



1652

CERTIFICATE OF MAILING
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED
WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT
POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:
ASSISTANT COMMISSIONER FOR PATENTS,
WASHINGTON, D.C. 20231, ON 20 December 2002

Audrey Boyd
December 20, 2002

Date

RECEIVED
DEC 30 2002
FBI CENTER 1600/2900

Attorney Docket No. P31731X1C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Anders, <i>et al.</i>	December 20, 2002
Serial No.:	10/071,338	Group Art Unit No.: 1652
Filed:	Herewith	Examiner: Kathleen Kerr
For:	Isolated 5R Clavams and Methods for Their Manufacture	

Assistant Commissioner of Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Applicants submitted a preliminary amendment to the application on February 13, 2002. Preliminary to the examination of this application, applicants respectfully request amendment of the above-identified application as follows:

Please amend the above-identified application as follows:

In the Claims

Please cancel claims 38-44.

Please add new claims 45-49.

45. A pharmaceutical composition which is free of one or more of the clavams selected from the group consisting of clavam-2-carboxylate, 2-hydroxymethylclavam, and 2-(3-allyl)clavam comprising clavulanic acid, obtainable by the process comprising the steps of:

(a) disrupting or otherwise making defective a DNA comprising one or more genes specific for 5S clavam biosynthesis in a *Streptomyces*, selected from the group consisting of orfup3 (SEQ ID NO: 2), orfup2 (SEQ ID NO: 3),